Algert Global LLC Has $2.73 Million Holdings in Omnicell, Inc. $OMCL

Key Points

• Algert Global LLC significantly increased its holdings in Omnicell, Inc. by 278.0%, owning approximately $2.73 million worth of shares as of the last quarter.
• Institutional investors now hold 97.70% of Omnicell's stock, with notable increases in positions by several firms, including Dimensional Fund Advisors, which boosted its holdings by 31.6%.
• Omnicell has received mixed analyst ratings, with recent price targets ranging from $34.00 to $62.00, and current consensus rating being a "Moderate Buy".

Algert Global LLC grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 278.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 78,032 shares of the company's stock after purchasing an additional 57,390 shares during the period. Algert Global LLC owned about 0.17% of Omnicell worth $2,728,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in OMCL. Invesco Ltd. grew its position in shares of Omnicell by 2.4% during the 4th quarter. Invesco Ltd. now owns 219,453 shares of the company's stock worth $9,770,000 after purchasing an additional 5,063 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in shares of Omnicell by 6.9% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock worth $213,000 after acquiring an additional 307 shares in the last quarter. Mariner LLC boosted its position in shares of Omnicell by 16.1% during the 4th quarter. Mariner LLC now owns 9,075 shares of the company's stock worth $404,000 after acquiring an additional 1,261 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Omnicell during the 4th quarter worth approximately $324,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after acquiring an additional 394,820 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on OMCL shares. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Piper Sandler reduced their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 11th. Benchmark reduced their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Bank of America increased their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Finally, Wells Fargo & Company increased their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Omnicell currently has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Stock Performance

Shares of Omnicell stock opened at $31.75 on Thursday. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The firm has a market capitalization of $1.46 billion, a P/E ratio of 63.50, a P/E/G ratio of 9.31 and a beta of 0.78. The company's 50 day moving average price is $29.49 and its two-hundred day moving average price is $32.07.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.